Sculptra^®

Yes. In the United States, Sculptra is FDA approved for correction of shallow-to-deep nasolabial fold contour deficiencies, other facial wrinkles, and fine lines and wrinkles in the cheek region in immune-competent people. Approval applies to specific indications and trained clinical use; it does not mean every facial or body use is approved.

Hyaluronic acid filler usually gives visible volume or contour immediately. Sculptra produces a more gradual change by supporting new collagen formation. It is not dissolved with hyaluronidase, so careful patient selection, placement and dosing are important.

Sculptra may create gradual facial volume restoration by stimulating collagen, so it can be considered when someone is searching for an alternative to immediate gel-based dermal filler. It is not a like-for-like substitute: Sculptra develops progressively, while hyaluronic acid filler adds visible gel volume immediately. The appropriate option depends on the treatment area, anatomy, timeline and desired degree of contouring.

No injectable treatment should be described as free from vascular-occlusion risk. Sculptra does not create volume in the same way as an immediate hyaluronic acid gel filler, but its FDA Instructions for Use still warn that accidental injection into a blood vessel can cause embolisation, vascular occlusion, ischaemia, infarction, vision loss or stroke. Current evidence does not establish a blanket claim that Sculptra is safer than every dermal filler. Technique, anatomy, treatment plane and clinician training are central to risk reduction.

A typical treatment plan is three sessions spaced at least three to four weeks apart, although the official instructions allow a single regimen of up to four sequential sessions. Your dermatologist may recommend fewer or more within approved guidance based on anatomy and response.

Results are gradual. Most clinical-study participants saw results as early as one month, with sustained improvement reported for up to two years. Timing and longevity vary by patient, treatment plan and biological response.

Many people return to routine activity quickly, but swelling, tenderness, redness, pain, bruising, bleeding, itching or lumps can occur. Your clinician will give individual aftercare instructions and explain which symptoms need urgent review.

US FDA-approved aesthetic indications include fine lines and wrinkles in the cheek region, shallow-to-deep nasolabial fold contour deficiencies and selected other facial wrinkles. Use in the lips, around the eyes or other areas requires specific caution and may be unapproved. Treatment areas should be determined by a trained clinician.

Sculptra is contraindicated for people with severe allergies or hypersensitivity to its components and for those with a history of keloid formation or hypertrophic scarring. Treatment should be postponed when the intended area has an active skin sore, infection or inflammation. A clinician must review pregnancy, breastfeeding, medicines, bleeding risk and medical history.

Common reactions include swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Delayed nodules or granulomas can occur. As with other facial injections, unintended injection into a blood vessel can cause rare but serious complications, including vision impairment, blindness, stroke or permanent scarring. Treatment should only be performed by an appropriately trained medical professional.

Cost depends on the number of vials, treatment areas and sessions needed. Riva provides a written treatment and cost plan after clinical assessment, before treatment begins.